Polycystic Ovary Syndrome
Conditions
Interventions
Gold Standard:1. Diagnosis of insulin resistance: euglycemic hyperinsulinemic clamp test, insulin resistance index (homeostasis model assessment-insulin resistance, HOMA-IR), HOMA-IR=(FPGxFINS)/ 22.5.
Index test:Fibroblast 
23, 
adiponectin 
Sponsors
Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
Female
Age
20 Years to 46 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for PCOS: Polycystic ovary syndrome was diagnosed according to the 2003 European Society of Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM) in Rotterdam, as follows: after excluding other known endocrine system-related gonadal diseases ( Such as congenital adrenal hyperplasia, androgen-secreting tumors and Cushing's syndrome), with any 2 of the following 3, can be diagnosed: (1) Thin ovulation and/or anovulation; (2) Clinical manifestations of hyperandrogenism and (or) hyperandrogenism; (3) Polycystic ovarian changes were found by ultrasound examination, that is, >= 12 follicles with a diameter of 2-9mm in one or both ovaries, and/or ovarian volume >= 10ml; 2. IR criteria: all patients underwent hyperinsulinemic-euglycemic clamp examination, and judged whether they had insulin resistance according to the results. Homeostasis model HOMA-IR: In 1999, WHO calculated the insulin resistance index (homeostasis model assessment-insulin resistance, HOMA-IR) in natural population based on fasting insulin (FINS) and fasting plasma glucose (FPG) values. , HOMA-IR=(FPGxFINS)/ 22.5.
Exclusion criteria
Exclusion criteria: 1. Those with severe cardiovascular and cerebrovascular diseases, liver and kidney dysfunction and other serious organic diseases; 2. The use of metformin and insulin sensitizers such as rosiglitazone, pioglitazone and other drugs to improve insulin resistance within 3 months, and the use of steroid hormones, parathyroid hormone, calcitonin, vitamin D preparations, etc. affecting the body's sex hormones, glucose and lipid metabolism , vitamin D metabolism and estrogen and progesterone drugs; 3. Those who have a history of drug abuse or alcoholism; 4. Women with a history of mental illness, malignant tumors, lactating women and women who have been taking contraceptives for a long time; 5. Patients with trauma, surgery, combined with severe acute and chronic infection within 3 months. 6. People with infectious diseases such as hepatitis and tuberculosis; 7. Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fibroblast Growth Factor 23; | — |
Countries
China
Contacts
Public ContactLiao Xin
Affiliated Hospital of Zunyi Medical University
Outcome results
None listed